DreamCIS Signs 'Strategic Partnership Agreement for Mutual Growth' with G2G Bio

[Asia Economy Reporter Lee Jung-yoon] DreamCIS, a global contract research organization (CRO), announced on the 18th that it has signed a strategic business agreement (MOU) for mutual growth with G2G Bio, a drug delivery system (DDS)-based new drug development specialist company.

This agreement is a broad one that includes overseas expansion and licensing accompanied by strategic investment (SI), as well as clinical trial strategies and clinical trials.

A DreamCIS official stated, "Successful clinical trials for multiple pipelines developed by G2G Bio, as well as cooperation in various areas such as licensing utilizing the network of its parent company, the global CRO TigerMed, will be possible," adding, "The number of global technology exports by domestic pharmaceutical and bio companies is increasing, and many of the technology acquiring companies are Chinese, so cooperation in the licensing field is expected."

According to statistics published by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, from 2017 to 2021, more than 20 domestic companies' technology acquiring companies were Chinese companies.

TigerMed, the No. 1 global CRO in China, said, "We will cooperate with our family company DreamCIS and our clients for success," and added, "We will actively support not only clinical trial areas but also global expansion including China."

Yoo Jung-hee, CEO of DreamCIS, said, "In the stagnant bio investment market, we are discovering promising bio venture companies and establishing and executing mid- to long-term plans to achieve a win-win through mutual cooperation with those companies," adding, "We will do our best to ensure that overseas projects of bio venture companies are successfully carried out."

DreamCIS was the first clinical CRO company to enter the KOSDAQ market in Korea. Additionally, as of the third quarter of this year, it recorded its highest-ever sales of 27.2 billion KRW and operating profit of 4 billion KRW.

This content was produced with the assistance of AI translation services.